BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26247772)

  • 1. Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
    Dong Y; Cao W; Ren J; Nair DS; Parker S; Jahnel JL; Swanson-Devlin TG; Beck JM; Mathews M; McNeil CJ; Upadhyaya M; Gao Y; Dong Q; Wang DZ
    PLoS One; 2015; 10(8):e0131487. PubMed ID: 26247772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
    Kim DJ; Kim DI; Kim SH; Lee KY; Heo JH; Han SW
    Neuroradiology; 2005 Aug; 47(8):616-21. PubMed ID: 15983773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
    Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA
    Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of blood pressure and collateral circulation in hyperacute ischemic stroke patients treated with intravenous thrombolysis.
    Rusanen H; Saarinen JT; Sillanpää N
    Cerebrovasc Dis; 2015; 39(2):130-7. PubMed ID: 25660943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
    Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
    Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment.
    Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome.
    Paliwal PR; Ahmad A; Shen L; Yeo LL; Loh PK; Ng KW; Chong VF; Ong BK; Venketasubramanian N; Sinha AK; Teoh HL; Bathla G; Chan BP; Sharma VK
    Cerebrovasc Dis; 2012; 33(5):446-52. PubMed ID: 22456065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous thrombolysis with tissue-plasminogen activator in small vessel occlusion.
    Paek YM; Lee JS; Park HK; Cho YJ; Bae HJ; Kim BJ; Park JM; Lee SJ; Cha JK; Park TH; Lee KB; Lee J; Lee BC; Kim JT; Kim DE; Shin DI; Kim WJ; Sohn SI; Choi JC; Hong KS
    J Clin Neurosci; 2019 Jun; 64():134-140. PubMed ID: 30952555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive.
    Saposnik G; Reeves MJ; Johnston SC; Bath PM; Ovbiagele B;
    Stroke; 2013 Oct; 44(10):2755-9. PubMed ID: 23887844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.